Latest news with #PeterHwang
Yahoo
a day ago
- Business
- Yahoo
OSR Holdings to acquire South Korea's medical device company Woori IO
Healthcare business OSR Holdings (OSRH) has signed a term sheet to acquire South Korea's medical device company, Woori IO (WORIO). Under the agreement, WORIO will be acquired by OSRH's Korean affiliate, OSR Holdings Co., Ltd (OSRK). WORIO will become OSRK's wholly owned subsidiary, with the shareholders of the former receiving new OSRK shares. These shares may be convertible into OSRH common stock on Nasdaq, subject to a $10 per OSRH share condition and other terms. WORIO shareholders have the option of converting their OSRK shares into OSRH shares at a fixed ratio. This conversion is contingent upon OSRH's stock price, hitting a minimum of $10.00 at any point within three years after the term sheet is executed. Should this price target not be achieved within the specified timeframe, both parties are committed to entering into renegotiations. A six-month exclusivity period is part of the agreement, during which OSRK will carry out confirmatory legal and financial due diligence. The goal is to conclude the acquisition within this timeframe. Via its subsidiaries, OSRH is involved in various healthcare sectors, including regenerative biologics, immuno-oncology, and the distribution of medical devices. OSRH CEO Peter Hwang said: "We believe this initial milestone with Woori IO aligns strongly with our mission to accelerate breakthrough healthcare innovations with global impact. "Woori IO's breakthrough noninvasive glucose monitoring platform, coupled with its high-profile partnership with global companies, puts OSRH in a position to become a first mover in this fast-growing global market." WORIO's platform is said to leverage near-infrared spectroscopy (NIRS) for the measurement of glucose levels, eliminating the need for finger pricks from diabetes patients. The technology has already undergone a proof-of-concept trial with the Korea University Hospital (Guro) to validate its prototype devices. WORIO is preparing for a larger confirmatory study to seek approval from the Korean Ministry of Food and Drug Safety (MFDS). The company's technology is also seen as a potential addition to wearable glucose monitoring devices such as smartwatches. "OSR Holdings to acquire South Korea's medical device company Woori IO" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Malaysian Reserve
09-07-2025
- Business
- Malaysian Reserve
OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG
BELLEVUE, Wash. and ZUG, Switzerland, July 9, 2025 /CNW/ — OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced the official roadmap for a targeted $50 million security token offering (STO) planned for launch in the second half of 2025 under Regulation D of the U.S. Securities Act. The token, with the working title OSRT, will be a securitized digital asset representing OSR Holdings' equity exposure and is designed to align with the company's blockchain-based capital strategy. As part of this roadmap, Taekwondo Access Credit (TAC)—a utility token that rewards participation and has growing adoption in the global Taekwondo community —will be accepted alongside Bitcoin (BTC) and Tether (USDT) as eligible currencies for subscription to the OSRT offering. Taekwondo remains one of the world's most widely practiced martial arts, with an estimated 70 million practitioners of all ages across 190 countries. TAC has been selected as one of the subscription tokens for the upcoming STO, alongside BTC and USDT, for its possible real-world utility with blood glucose monitoring devices, details of which OSRH intends to announce in a forthcoming press release. BCM Europe intends to convert a substantial portion of its TAC holdings into BTC or USDT through market-based transactions prior to its anticipated participation. Due to the convertibility of TAC into OSRT and to ensure compliance and mitigate potential insider trading concerns, BCM Europe AG, the issuer of TAC and the largest shareholder of OSRH, will not be permitted to use TAC directly in subscribing to the OSRT offering. Other interested and eligible subscribers of OSRT will be able to use BTC, USDT, or TAC to acquire OSRT tokens. 'Our upcoming STO is not just a tokenization of our equity – it's a foundational element of our long-term capital and treasury strategy,' said Peter Hwang, CEO of OSRH. 'We believe that our combined $50 million STO plan and $80 million equity line of credit (ELOC) from White Lion GBM Innovation Fund provides a credible and achievable path towards building a $100 million Bitcoin and USDT reserve on our balance sheet.' Key Elements of the OSRT Security Token Roadmap: Plan for up to $50 Million STO Under Reg D:OSR Holdings aims to raise up to $50 million in digital assets via the OSRT token in the second half of 2025, offered under Regulation D, targeting accredited investors. Eligibility of BTC, USDT, and TAC:OSRT will be offered to accredited investors who may subscribe using BTC, USDT, or TAC, enabling diversified participation and aligning with OSRH's existing blockchain ecosystem partnerships. Special Restrictions for BCM Europe AG:While TAC will be accepted from eligible investors in the STO, BCM Europe AG, as the issuer of TAC and a major shareholder of OSR Holdings, will not be permitted to subscribe using TAC directly. Instead, BCM Europe will convert its TAC holdings into BTC or USDT through market-based transactions, a process designed to avoid conflicts of interest and align with best practices on insider participation. ELOC-Backed Liquidity Plan:In parallel to the STO, OSR Holdings continues to draw from its $80 million ELOC from White Lion GBM Innovation Fund, further reinforcing its capital base and enabling the company to scale its crypto holdings toward a realistic $100 million reserve. Crypto-Healthcare Convergence Strategy:OSRH is integrating decentralized finance with healthcare innovation, supported by its unique ecosystem that includes TAC, which is already actively used within the global Taekwondo community. Additional announcements on TAC real-world integration with digital healthcare are planned for 3Q2025. 'This roadmap represents a significant evolution in how public healthcare companies can engage with digital finance,' said Chris Bang, Chief Financial Officer of OSRH. 'By structuring this offering with both transparency and accessibility in mind, we aim to reach a new generation of investors while maintaining regulatory discipline and operational integrity.' About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting-edge research and development. For more information, visit About BCM Europe AG BCM Europe AG is a healthcare and blockchain investment firm based in Zug, Switzerland. BCM Europe is the founding organization behind Taekwondo Access Credit (TAC), a utility token adopted globally in the martial arts community and traded on centralized exchanges. Forward-Looking Statements This press release includes forward-looking statements regarding the expected timeline and design of the OSRT security token offering and BCM Europe's participation strategy. These statements are subject to risks and uncertainties, including but not limited to regulatory approvals, market volatility, and technical readiness. The OSRT Token offering has not yet been approved by the Board of OSR Holdings and will proceed only upon satisfaction of applicable legal and regulatory requirements. Contact Information OSR Holdings, Relationsir@ BCM Europe AGMedia Relationsgroup@
Cision Canada
09-07-2025
- Business
- Cision Canada
OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG
BELLEVUE, Wash. and ZUG, Switzerland, July 9, 2025 /CNW/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced the official roadmap for a targeted $50 million security token offering (STO) planned for launch in the second half of 2025 under Regulation D of the U.S. Securities Act. The token, with the working title OSRT, will be a securitized digital asset representing OSR Holdings' equity exposure and is designed to align with the company's blockchain-based capital strategy. As part of this roadmap, Taekwondo Access Credit (TAC)—a utility token that rewards participation and has growing adoption in the global Taekwondo community —will be accepted alongside Bitcoin (BTC) and Tether (USDT) as eligible currencies for subscription to the OSRT offering. Taekwondo remains one of the world's most widely practiced martial arts, with an estimated 70 million practitioners of all ages across 190 countries. TAC has been selected as one of the subscription tokens for the upcoming STO, alongside BTC and USDT, for its possible real-world utility with blood glucose monitoring devices, details of which OSRH intends to announce in a forthcoming press release. BCM Europe intends to convert a substantial portion of its TAC holdings into BTC or USDT through market-based transactions prior to its anticipated participation. Due to the convertibility of TAC into OSRT and to ensure compliance and mitigate potential insider trading concerns, BCM Europe AG, the issuer of TAC and the largest shareholder of OSRH, will not be permitted to use TAC directly in subscribing to the OSRT offering. Other interested and eligible subscribers of OSRT will be able to use BTC, USDT, or TAC to acquire OSRT tokens. "Our upcoming STO is not just a tokenization of our equity – it's a foundational element of our long-term capital and treasury strategy," said Peter Hwang, CEO of OSRH. "We believe that our combined $50 million STO plan and $80 million equity line of credit (ELOC) from White Lion GBM Innovation Fund provides a credible and achievable path towards building a $100 million Bitcoin and USDT reserve on our balance sheet." Key Elements of the OSRT Security Token Roadmap: Plan for up to $50 Million STO Under Reg D: OSR Holdings aims to raise up to $50 million in digital assets via the OSRT token in the second half of 2025, offered under Regulation D, targeting accredited investors. Eligibility of BTC, USDT, and TAC: OSRT will be offered to accredited investors who may subscribe using BTC, USDT, or TAC, enabling diversified participation and aligning with OSRH's existing blockchain ecosystem partnerships. Special Restrictions for BCM Europe AG: While TAC will be accepted from eligible investors in the STO, BCM Europe AG, as the issuer of TAC and a major shareholder of OSR Holdings, will not be permitted to subscribe using TAC directly. Instead, BCM Europe will convert its TAC holdings into BTC or USDT through market-based transactions, a process designed to avoid conflicts of interest and align with best practices on insider participation. ELOC-Backed Liquidity Plan: In parallel to the STO, OSR Holdings continues to draw from its $80 million ELOC from White Lion GBM Innovation Fund, further reinforcing its capital base and enabling the company to scale its crypto holdings toward a realistic $100 million reserve. Crypto-Healthcare Convergence Strategy: OSRH is integrating decentralized finance with healthcare innovation, supported by its unique ecosystem that includes TAC, which is already actively used within the global Taekwondo community. Additional announcements on TAC real-world integration with digital healthcare are planned for 3Q2025. "This roadmap represents a significant evolution in how public healthcare companies can engage with digital finance," said Chris Bang, Chief Financial Officer of OSRH. "By structuring this offering with both transparency and accessibility in mind, we aim to reach a new generation of investors while maintaining regulatory discipline and operational integrity." About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting-edge research and development. For more information, visit About BCM Europe AG BCM Europe AG is a healthcare and blockchain investment firm based in Zug, Switzerland. BCM Europe is the founding organization behind Taekwondo Access Credit (TAC), a utility token adopted globally in the martial arts community and traded on centralized exchanges. Forward-Looking Statements This press release includes forward-looking statements regarding the expected timeline and design of the OSRT security token offering and BCM Europe's participation strategy. These statements are subject to risks and uncertainties, including but not limited to regulatory approvals, market volatility, and technical readiness. The OSRT Token offering has not yet been approved by the Board of OSR Holdings and will proceed only upon satisfaction of applicable legal and regulatory requirements. Contact Information OSR Holdings, Inc. Investor Relations [email protected] +82-31-948-9419 BCM Europe AG Media Relations [email protected] +41-41-725-0800 SOURCE OSR Holdings Inc.
Associated Press
08-07-2025
- Business
- Associated Press
OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG
BELLEVUE, Wash. and ZUG, Switzerland, July 8, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced the official roadmap for a targeted $50 million security token offering (STO) planned for launch in the second half of 2025 under Regulation D of the U.S. Securities Act. The token, with the working title OSRT, will be a securitized digital asset representing OSR Holdings' equity exposure and is designed to align with the company's blockchain-based capital strategy. As part of this roadmap, Taekwondo Access Credit (TAC)—a utility token that rewards participation and has growing adoption in the global Taekwondo community —will be accepted alongside Bitcoin (BTC) and Tether (USDT) as eligible currencies for subscription to the OSRT offering. Taekwondo remains one of the world's most widely practiced martial arts, with an estimated 70 million practitioners of all ages across 190 countries. BCM Europe intends to convert a substantial portion of its TAC holdings into BTC or USDT through market-based transactions prior to its anticipated participation. Due to the convertibility of TAC into OSRT and to ensure compliance and mitigate potential insider trading concerns, BCM Europe AG, the issuer of TAC and the largest shareholder of OSR Holdings, will not be permitted to use TAC directly in subscribing to the OSRT offering. Other interested and eligible subscribers of OSRT will be able to use BTC, USDT, or TAC to acquire OSRT tokens. 'Our upcoming STO is not just a tokenization of our equity – it's a foundational element of our long-term capital and treasury strategy,' said Peter Hwang, CEO of OSR Holdings. 'We believe that our combined $50 million STO plan and $80 million equity line of credit (ELOC) from White Lion GBM Innovation Fund provides a credible and achievable path towards building a $100 million Bitcoin and USDT reserve on our balance sheet.' Key Elements of the OSRT Security Token Roadmap: 'This roadmap represents a significant evolution in how public healthcare companies can engage with digital finance,' said Chris Bang, Chief Financial Officer of OSR Holdings. 'By structuring this offering with both transparency and accessibility in mind, we aim to reach a new generation of investors while maintaining regulatory discipline and operational integrity.' About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting-edge research and development. For more information, visit About BCM Europe AG BCM Europe AG is a healthcare and blockchain investment firm based in Zug, Switzerland. BCM Europe is the founding organization behind Taekwondo Access Credit (TAC), a utility token adopted globally in the martial arts community and traded on centralized exchanges. Forward-Looking Statements This press release includes forward-looking statements regarding the expected timeline and design of the OSRT security token offering and BCM Europe's participation strategy. These statements are subject to risks and uncertainties, including but not limited to regulatory approvals, market volatility, and technical readiness. The OSRT Token offering has not yet been approved by the Board of OSR Holdings and will proceed only upon satisfaction of applicable legal and regulatory requirements. Contact Information OSR Holdings, Inc. Investor Relations [email protected] +82-31-948-9419 BCM Europe AG Media Relations [email protected] +41-41-725-0800 View original content to download multimedia: SOURCE OSR Holdings Inc.
Korea Herald
03-04-2025
- Business
- Korea Herald
OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies
SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund ("Innovation Fund"). Under this agreement, OSR has the right, but not the obligation, to sell up to $80 million in common stock to Innovation Fund over time, which will prospectively provide OSR with critical funding to accelerate its mission of improving patient outcomes worldwide. Transforming Global Healthcare Through Innovation OSR Holdings is committed to transforming the healthcare landscape through a diverse portfolio of cutting-edge biomedical initiatives. The company's global network spans the United States, Europe, and Asia, focusing on oncology, immunotherapy, and medical devices. Among its key subsidiaries, OSR is advancing Vaximm, a Swiss-based biotech developing a novel GBM vaccine (VXM01) aimed at enhancing immune response against glioblastoma. "This transaction is a major cornerstone in our plans to bring transformative therapies to market," said Peter Hwang, CEO, OSR Holdings. "Glioblastoma remains one of the most challenging cancers, and we anticipate that establishing this financing facility will enable us to advance our Vaximm immunotherapy platform and other innovative healthcare solutions. "We anticipate that this collaboration with Innovation Fund will also introduce our Vaximm VXM01 program into Innovate GBM's ecosystem of researchers, clinicians, regulatory experts, investors, policymakers, and patient advocates; the same ecosystem that initially connected OSR and Innovation Fund. Together, we are committed to transforming glioblastoma treatment from a fragmented approach to one characterized by cooperation, transparency, and progress," said Constance Höfer, CSO, OSR Holdings. Innovate GBM: Expanding the Ecosystem to De-Risk Investment Innovate GBM is a 501(c)(3) nonprofit that is dedicated to centralizing and expanding the glioblastoma innovation ecosystem. Innovate GBM unites scientists, clinicians, investors, patient advocates, and regulatory experts, creating an interconnected community that streamlines collaboration, amplifies resources, and accelerates investment into glioblastoma R&D. By bridging biotech companies, research institutions, and capital providers, Innovate GBM facilitates efficient funding toward promising therapies, moving groundbreaking research from academia into clinical settings rapidly. The OSR and Innovation Fund transaction is an example of the ecosystem at work. "This transaction embodies Innovate GBM's core vision," said Kush Thukral, Co-Executive Director of Innovate GBM. "By bringing OSR Holdings and the GBM Innovation Fund together in our collaborative ecosystem, we accelerate capital deployment, enhance innovation, and ensure promising therapies reach patients faster." White Lion GBM Innovation Fund: A Strategic Investment Partner The White Lion GBM Innovation Fund, one of Innovate GBM's core sponsors, focuses on strategic funding opportunities in glioblastoma drug development. The Innovation Fund leverages the ecosystem curated by Innovate GBM to gain insights from the GBM community—including neuro-oncologists, scientists, and patient advocacy groups—to guide capital allocation toward the most impactful opportunities. About OSR Holdings, Inc. OSR Holdings, Inc. is a global healthcare company dedicated to advancing biomedical innovation. Through its subsidiaries, OSR is engaged in oncology immunotherapies, degenerative disease biologics, and medical device distribution. OSR's vision is to acquire and operate a portfolio of innovative healthcare companies, improving patient care through cutting-edge research and development. For more information, visit Innovate GBM is a 501(c)(3) nonprofit organization dedicated to expanding the glioblastoma ecosystem by uniting researchers, investors, clinicians, and patient advocates. By centralizing resources and facilitating strategic partnerships, Innovate GBM helps de-risk investment into GBM innovation, ensuring that funding flows efficiently to the most promising treatments. For more information, visit
